阿法替尼
Afatinib.
作者信息
Wecker Helga, Waller Cornelius F
机构信息
Department of Haematology, Oncology and Stem Cell Transplantation, University Medical Centre Freiburg, and Faculty of Medicine, University of Freiburg, Hugstetter Str. 55, 79106, Freiburg, Germany.
出版信息
Recent Results Cancer Res. 2018;211:199-215. doi: 10.1007/978-3-319-91442-8_14.
Afatinib (BIBW 2992, US: Gilotrif, other countries: Giotrif©) is an irreversible blocker of the ErbB family, acting at the tyrosine kinases of these proteins. In 2013, it was approved by the FDA and the EMA for the treatment of adults with advanced, EGFR mutation-positive non-small-cell lung cancer. Further investigations for the treatment of many other tumors with afatinib, e.g., HNSCC and breast cancer, are ongoing.
阿法替尼（BIBW 2992，美国：吉泰瑞，其他国家：Giotrif©）是一种不可逆的表皮生长因子受体（ErbB）家族阻滞剂，作用于这些蛋白的酪氨酸激酶。2013年，它被美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）批准用于治疗晚期表皮生长因子受体（EGFR）突变阳性的非小细胞肺癌成人患者。目前正在对阿法替尼治疗许多其他肿瘤，如头颈部鳞状细胞癌（HNSCC）和乳腺癌，进行进一步研究。
Zotero 插件